BPC-157 / TB-500 Peptide Blend: A Research Review of the Two-Component Repair Preparation, Its Separate Evidence Bases and the Absence of Combination Data

By Peptide Insider Research Team · 12 min read · Last updated 9 September 2026

The BPC-157 / TB-500 combination — catalogued by research suppliers under dozens of labels, from bpc157 tb500 and bpc-157 tb-500 to bpc 157 tb 500 blend — pairs two peptides from unrelated biological lineages that have each been studied, separately, in preclinical models of soft-tissue repair. BPC-157 is a synthetic pentadecapeptide derived from a sequence in a gastric juice protein [1,2]; TB-500 is the N-terminally acetylated 17–23 fragment of thymosin β4 (Tβ4), the actin-sequestering motif of a 43-residue protein [3,4]. This review examines what the peer-reviewed literature actually supports for each component, why the two are frequently paired, and — critically — the fact that no controlled study has evaluated the combination itself. All content is provided strictly for research reference.

Introduction

Few pairings in the research-peptide catalogue are as ubiquitous as tb-500 and bpc-157. The usual rationale is mechanistic complementarity: BPC-157 has been studied primarily in the context of angiogenesis-linked healing of gastrointestinal, tendon, ligament, muscle and bone tissue [2,5,6], while Tβ4 and its fragments have been studied for actin-dependent cell migration, endothelial tube formation and reduced inflammatory cell infiltration in cardiac, corneal and cutaneous injury models [3,7,8,9]. On paper the two act at different nodes of the same repair cascade.

That rationale is entirely inferential. PubMed returns no controlled or observational study in which bpc 157 and tb500 were co-administered and compared against either agent alone. This review therefore treats the blend as two separate evidence bases whose intersection remains hypothetical.

Biological background: the soft-tissue repair cascade

Soft-tissue repair proceeds through overlapping phases — haemostasis and inflammation, proliferation with angiogenesis and matrix deposition, and prolonged collagen remodelling [10]. Tendon and ligament complete this sequence slowly because of low cellularity and limited vascular supply [6,10].

BPC-157 studies emphasise early re-establishment of blood flow and endothelial growth-factor receptor up-regulation [5,11,12]; Tβ4 studies emphasise directional migration of endothelial, epicardial and keratinocyte populations [3,7,13]. Whether these actions are additive, redundant or interfering when combined is an open question.

Compound structure and mechanism of action, component by component

BPC-157 (Body Protection Compound 157)

BPC-157 is a 15-amino-acid synthetic peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; molecular weight ≈1,419 Da) corresponding to a partial sequence of a protein identified in human gastric juice [1,2]. It has been reported to remain stable in human gastric juice for more than 24 hours, unlike carrier-dependent growth factors such as EGF, FGF and VEGF [2,5]. Reported mechanisms include:

• VEGFR2 up-regulation and internalisation. In human vascular endothelial cells BPC-157 increased VEGFR2 mRNA and protein and promoted receptor internalisation, activating the VEGFR2–Akt–eNOS axis; the endocytosis inhibitor dynasore abolished these effects. In a rat hind-limb ischaemia model the peptide accelerated blood-flow recovery and increased vessel counts [11].
• Tendon fibroblast outgrowth and GH-receptor expression. In rat Achilles tendon explants BPC-157 increased tendon outgrowth, fibroblast survival under oxidative stress and migration via FAK–paxillin phosphorylation [12]; in a separate study it increased, in a concentration-dependent manner, growth-hormone receptor expression in tendon fibroblasts, potentiating the proliferative response to GH [15].
• Early-growth-response signalling. In wound tissue the compound (then coded PL 14736) increased expression of egr-1 and its co-repressor NAB2, correlating with improved granulation and collagen organisation [16].
• Nitric-oxide system interaction. A substantial literature describes BPC-157 counteracting both L-NAME-induced hypertension and L-arginine-induced hypotension in rats, interpreted as modulation of the NO system rather than simple agonism or antagonism [17].

TB-500 (Ac-LKKTETQ, thymosin β4 fragment 17–23)

Doping-control laboratories characterised the material sold as TB-500 by high-resolution mass spectrometry as the N-terminally acetylated heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln — residues 17–23 of Tβ4 — and synthesised reference standards for detection in plasma and urine [4,18]. This segment contains the LKKTET motif responsible for Tβ4's binding to monomeric G-actin, the property from which the parent protein's name as an "actin-sequestering" peptide derives [3,19]. Key findings for the parent protein and its actin-binding region include:

• Directional endothelial migration and angiogenesis. Tβ4 stimulated chemotactic migration of human umbilical vein endothelial cells and tube formation on Matrigel; a subsequent study showed that the actin-binding domain alone reproduced the pro-migratory activity [20,21].
• Cardiac cell survival via ILK–Akt. In mice Tβ4 activated integrin-linked kinase, increased Akt phosphorylation and promoted cardiomyocyte survival and migration after coronary ligation [7]; a later study reported epicardial progenitor mobilisation and neovascularisation [13].
• Cutaneous and corneal wound closure. Topical or intraperitoneal Tβ4 accelerated re-epithelialisation and collagen deposition in full-thickness rat wounds [8], and reduced inflammatory cell infiltration while promoting epithelial migration after corneal alkali injury [9].
• Ac-SDKP metabolite. Cleavage of Tβ4's N-terminus releases Ac-SDKP, an anti-fibrotic tetrapeptide that cannot be generated from the 17–23 fragment [14].

Component comparison

Attribute	BPC-157	TB-500
Origin	Partial sequence of a gastric-juice protein [1]	Fragment 17–23 of thymosin β4 [4]
Length / mass	15 residues, ≈1,419 Da [2]	7 residues, ≈889 Da (acetylated) [4]
Best-characterised pathway	VEGFR2–Akt–eNOS; FAK–paxillin; egr-1/NAB2; NO system [11,12,16,17]	G-actin sequestration (LKKTET); ILK–Akt; endothelial chemotaxis [3,7,20]
Dominant models	Rat tendon, muscle, ligament, GI, vascular [5,6,22]	Mouse heart, rat skin, mouse/rat cornea [7,8,9]
Relationship to a natural parent	Synthetic; parent protein not fully characterised	Fragment of a well-characterised 43-aa protein; fragment ≠ full-length [4,19]
Combination data	None in peer-reviewed literature as of September 2026

Nomenclature and catalogue variants

Because the blend is a catalogue construct rather than a named pharmacological entity, it appears in supplier listings and search queries under an unusually large number of labels. Researchers reconciling literature, certificates of analysis and inventory records should recognise the following as referring to the same two-component preparation:

Label family	Variants encountered in catalogues and search queries
Slash notation	bpc-157/tb-500 · bpc157/tb500 · bpc 157/tb 500 · bpc157 / tb500 · bpc-157 / tb-500 · peptides - bpc157/tb500
Space or hyphen notation	bpc157 tb500 · bpc-157 tb-500 · bpc-157 tb500 · bpc157-tb500 · tb500 bpc157 · bpc tb 500 · bpc 157 peptide tb500 · peptide bpc 157 tb 500
Conjunction notation	bpc 157 and tb500 · tb-500 and bpc-157 · tb 500 and bpc 157 · bpc-157 and tb 500 · bpc 157 & tb 500 · bpc 157 + tb500 · bpc-157 + tb-500 · bpc 157 and tb 500 peptide · peptides bpc 157 and tb 500 · bpc-157 and tb-500.
"Blend" descriptors	bpc 157 tb 500 blend · bpc157 tb500 blend · bpc 157 tb500 blend · bpc 157 and tb 500 blend · bpc tb500 blend · bpc157 tb500 peptides · bpc 157 tb500 peptides
Common misspellings	bp157 tb500 · bcp157 tb500 · boc157/tb500 · bp 157 and tb500

The catalogue phrase "bpc-157 tb-500 peptide blend scientific research" should not be read as implying combination-specific research exists; it does not. And because the components differ five-fold in mass, a certificate of analysis for a blended vial should report identity and purity for each peptide separately [4,18,23].

Evidence by research domain

Research domain	Typical models	Reported findings (component)	Evidence maturity
Tendon healing	Rat Achilles transection; tendon-to-bone detachment; tendon explants	BPC-157: improved biomechanical and histological healing, fibroblast outgrowth, GH-receptor up-regulation [6,12,15,24]	Preclinical, single-laboratory dominated
Muscle and ligament	Rat quadriceps/gastrocnemius transection; corticosteroid-impaired healing; MCL transection	BPC-157: restored function and histology in corticosteroid-impaired muscle healing; improved ligament healing [22,25]	Preclinical
Cutaneous wounds	Rat full-thickness wounds; diabetic and burn models	Tβ4: faster re-epithelialisation, collagen deposition [8]; BPC-157: improved granulation, egr-1/NAB2 expression, burn healing [5,16]	Preclinical (both); Tβ4 also in early clinical dermal studies
Angiogenesis / vascular	CAM assay; HUVEC tube formation; rat hind-limb ischaemia; Matrigel	BPC-157: VEGFR2-dependent vessel formation [11]; Tβ4: endothelial chemotaxis and tube formation via actin-binding domain [20,21]	Preclinical, mechanistically well defined
Cardiac repair	Mouse coronary ligation	Tβ4: ILK–Akt activation, cardiomyocyte survival, epicardial progenitor mobilisation [7,13]	Preclinical (full-length Tβ4, not fragment)
Ocular surface	Mouse/rat alkali injury; human dry-eye trial	Tβ4: reduced inflammatory infiltrate, epithelial migration [9]; Phase II ophthalmic solution trial reported sign/symptom improvements [26]	Preclinical + Phase II (Tβ4 only)
Combination (BPC-157 + TB-500)	—	No controlled study identified	None

Tendon and ligament models

The most-cited BPC-157 findings come from rat Achilles tendon transection, where treated animals showed improved load-to-failure, better-organised collagen and more complete bridging of the gap than controls [6], and from a tendon-to-bone detachment model in which healing of the detached Achilles insertion was reported to be markedly better with the peptide [24]. Explant work later attributed part of this effect to increased tendon outgrowth and fibroblast migration [12]. Tendon-specific data for TB-500 or full-length Tβ4 are sparse; relevance to tendon is extrapolated from cell-motility effects [3,20].

Muscle injury and impaired healing

In rats whose muscle healing was impaired with systemic corticosteroid, BPC-157 was associated with restored functional recovery and histological repair relative to impaired controls [22]; similar findings were reported in medial collateral ligament transection [25].

Cutaneous wounds and angiogenesis

Both components have independent wound data. Tβ4 accelerated closure of full-thickness rat wounds with increased collagen and keratinocyte migration [8], while BPC-157 improved granulation tissue and collagen organisation with concomitant egr-1/NAB2 induction [16] and has been reviewed across incisional, excisional, burn and diabetic-ulcer models [5]. The angiogenesis literature — VEGFR2 trafficking for BPC-157 [11], actin-dependent endothelial chemotaxis for Tβ4 [20,21] — is where an interaction hypothesis could be tested in a factorial design.

Combination evidence

Despite the prevalence of bpc157 tb500 blend preparations in the research market, we identified no peer-reviewed study — in vitro, in vivo or clinical — that administered both peptides together with single-agent controls. Synergy claims therefore rest on juxtaposition of separate literatures; for anyone designing research with the combination, single-agent arms are not optional.

Limitations and research considerations

• Model dependence. The great majority of BPC-157 evidence derives from rat models produced by a single research network in Zagreb; independent replication is limited [5,6,27]. Tβ4 data are more geographically distributed but concern the full-length protein far more often than the 17–23 fragment.
• Fragment versus full-length. TB-500 retains the actin-binding LKKTET motif but lacks the N-terminal region that yields Ac-SDKP and the C-terminal region implicated in some receptor interactions; results obtained with 43-residue Tβ4 cannot be assumed to transfer to the heptapeptide [4,14,19].
• No combination data. Additive, synergistic or antagonistic interaction between the components has never been measured. A factorial design (vehicle / BPC-157 / TB-500 / both) is the minimum required to make any statement about the blend as such.
• Regulatory status. Both peptides are subjects of published doping-control detection methods [4,18,23]; neither is an approved pharmaceutical anywhere. They are research reagents only.
• Analytical identity of blended vials. A single purity percentage for a blended lot is uninformative; researchers should expect component-resolved HPLC and mass-spectrometric identity data.

Where to source for research

Two-component BPC-157/TB-500 preparations and the individual peptides are listed by several research-reagent suppliers; researchers should prioritise those publishing component-resolved certificates of analysis. Short Chain Aminos lists BPC-157, TB-500 and the combined preparation with batch documentation; BioPep and Catalyst Research supply the individual peptides for laboratories preferring to prepare their own controlled ratios; and Apex Research Services lists both peptides for research use. Our supplier evaluation guide and suppliers directory describe the documentation to request. All listings are for laboratory research only.

Frequently asked research questions

What is bpc-157/tb-500 and why are the two peptides combined?

The label bpc-157/tb-500 denotes a two-component research preparation of the gastric pentadecapeptide BPC-157 and TB-500, the acetylated 17–23 fragment of thymosin β4. They are combined on the mechanistic inference that BPC-157's VEGFR2-linked angiogenic effects and Tβ4's actin-dependent cell-migration effects address different stages of soft-tissue repair. No controlled study has tested the combination [4,11,20].

Is there scientific research on the bpc 157 tb 500 blend specifically?

No. Searches of PubMed identify separate preclinical literatures for each component but no in vitro, animal or clinical study administering bpc 157 and tb 500 together with single-agent controls. Phrases such as "bpc-157 tb-500 peptide blend scientific research" in catalogue descriptions refer to the component literatures, not to combination data. Any synergy claim is currently hypothesis, not finding [5,6].

How do tb-500 and bpc-157 differ in mechanism?

BPC-157 has been reported to up-regulate and internalise VEGFR2, activate Akt–eNOS, increase egr-1/NAB2 expression and modulate the nitric-oxide system in rat models [11,16,17]. TB-500 contains the LKKTET actin-binding motif of thymosin β4; the parent protein promotes endothelial chemotaxis, ILK–Akt signalling and reduced inflammatory infiltration [3,7,20]. The pathways are distinct but converge on angiogenesis and cell migration.

Is TB-500 the same as thymosin beta-4?

No. Thymosin β4 is a 43-residue protein; TB-500 is a synthetic seven-residue fragment (Ac-LKKTETQ) corresponding to residues 17–23 that was characterised by doping-control laboratories in 2012 [4]. The fragment retains actin binding but cannot generate the Ac-SDKP metabolite or engage regions outside the motif, so full-length Tβ4 findings do not automatically apply [14,19].

What evidence exists for bpc157 tb500 peptides in tendon research?

Tendon evidence belongs almost entirely to BPC-157: rat Achilles transection and tendon-to-bone detachment studies reported improved biomechanical and histological healing, and explant studies showed increased fibroblast outgrowth, survival and migration via FAK–paxillin phosphorylation [6,12,24]. Direct tendon studies of TB-500 are lacking; its contribution in bpc157 tb500 peptides preparations is inferred from cell-motility data.

What should a certificate of analysis for bpc157 tb500 blend show?

Because the two peptides differ roughly five-fold in molecular mass, a blended lot should carry component-resolved data: separate HPLC purity values, mass-spectrometric identity confirming ≈1,419 Da for BPC-157 and ≈889 Da for acetylated TB-500, and stated net peptide content for each. A single aggregate purity figure cannot distinguish the components [4,18,23].

Are BPC-157 and TB-500 approved compounds?

Neither peptide is an approved pharmaceutical in any jurisdiction, and both appear in published anti-doping detection methods [4,18,23]. Full-length thymosin β4 has entered clinical trials in ophthalmic and dermal indications [26], but those data concern the parent protein, not TB-500. Both components are supplied strictly as research-use-only reagents, not for human or veterinary use.

Works Cited

1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–1632. PMID 21548867.
2. Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533. doi:10.3389/fphar.2021.627533. PMC8275860.
3. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429. PMID 16099219.
4. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733–738. doi:10.1002/dta.1402. PMID 22962027.
5. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972–1989. PMID 29998800.
6. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976–983. PMID 14554208.
7. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–472. PMID 15565145.
8. Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364–368. PMID 10469335.
9. Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD. Thymosin β4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293–299. PMID 11950239.
10. Voleti PB, Buckley MR, Soslowsky LJ. Tendon healing: repair and regeneration. Annu Rev Biomed Eng. 2012;14:47–71. PMID 22809137.
11. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323–333. doi:10.1007/s00109-016-1488-y. PMID 27847966.
12. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. PMID 21030672.
13. Smart N, Risebro CA, Melville AA, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–182. PMID 17108969.
14. Cavasin MA. Therapeutic potential of thymosin-β4 and its derivative N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) in cardiac healing after infarction. Am J Cardiovasc Drugs. 2006;6(5):305–311. PMID 17083265.
15. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. PMID 25415472.
16. Tkalcević VI, Cuzić S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healed wounds and the potential role of egr-1 expression. Eur J Pharmacol. 2007;570(1-3):212–221. PMID 17628536.
17. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126–1135. PMID 23755725.
18. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57–69. PMID 23084823.
19. Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. β-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205–220. PMID 11311852.
20. Malinda KM, Goldstein AL, Kleinman HK. Thymosin β4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474–481. PMID 9194528.
21. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin β4 promotes angiogenesis. FASEB J. 2003;17(14):2103–2105. PMID 14500546.
22. Pevec D, Novinscak T, Brcic L, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010;16(3):BR81–BR88. PMID 20190676.
23. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017;9(10):1490–1498. doi:10.1002/dta.2152.
24. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982–989. PMID 16583442.
25. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155–1161. PMID 20225319.
26. Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. 2015;9:877–884. PMID 26060396.
27. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159. PMID 30915550.

Research Use Only. All content strictly for research reference. BPC-157, TB-500 and their combination are laboratory research reagents, not for human or veterinary use. Nothing on this page constitutes medical advice or a recommendation for any use.

Explore related compounds: BPC-157 research review · TB-500 and thymosin β4 research review · KLOW blend (GHK-Cu, BPC-157, TB-500, KPV) · GHK-Cu review